Lupin has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market generic version of Benicar tablets, 5 mg, 20 mg and 40 mg. Benicar tablets had US sales of $1,036 million, as per IMS MAT December 2016.
Lupin's Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Inc.'s Benicar tablets. It is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
